A5020755903- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Glycosylation and Glycoproteins Research
- vaccines and immunoinformatics approaches
- Glioma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Galectins and Cancer Biology
- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Immune Response and Inflammation
- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- HIV Research and Treatment
- Immune cells in cancer
- Blood groups and transfusion
- Melanoma and MAPK Pathways
Celldex Therapeutics (United States)
2016-2025
University at Buffalo, State University of New York
2020
Roswell Park Comprehensive Cancer Center
2020
Hampton University
2019
Mayo Clinic
2012-2017
Sarah Cannon
2014-2017
Mayo Clinic in Arizona
2017
Mary Crowley Cancer Research Center
2017
Tennessee Oncology
2017
Yale University
2017
Nineteen patients with high-risk resected stage III and IV melanoma were immunized three tumor antigen epitope peptides from gp100, MART-1, tyrosinase emulsified adjuvant Montanide ISA 51 received a fully human anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclonal antibody MDX-010. Each of cohorts escalating doses vaccine primarily to evaluate the toxicities maximum-tolerated dose (MTD) MDX-010 vaccine. pharmacokinetics immune responses secondary end points.Peptide immunizations...
The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists the unique EGFRvIII peptide sequence conjugated keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses promising progression-free overall This multicenter, single-arm clinical trial (ACT III) performed confirm...
Dendritic cell targeting safely leads to integrated humoral and cellular immunity when combined with TLR agonists in cancer patients.
Two subsets of conventional dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse human. The two cDCs are specialized antigen-presenting that initiate T immunity tolerance. In the mouse, a migratory cDC precursor (pre-CDC) originates from defined progenitors bone marrow (BM). Small numbers short-lived pre-CDCs travel through blood replace peripheral organs, maintaining homeostasis highly dynamic pool. However, identity distribution immediate to human has not...
Abstract Purpose: Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer (mCRPC). Novel combinations may enhance immunotherapy efficacy. Patients and Methods: We conducted an open-label, non-comparative platform trial (NCT03835533) in mCRPC to assess nivolumab-based combinations. The cohorts were: A) bempegaldesleukin 0.006 mg/kg nivolumab 360 mg intravenously Q3W, B) stereotactic body radiation therapy 30-50 Gray, CDX-301 75 μg/kg...
MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy patients with relapsed or refractory CD30+ lymphomas, sequential phase I II studies were performed.In portion, was administered intravenously at doses 0.1, 1, 5, 10 mg/kg weekly for 4 weeks to cohorts three six patients. Twenty-one patients--16 Hodgkin's lymphoma (HL),...
Human BDCA3(+) dendritic cells (DCs), the proposed equivalent to mouse CD8α(+) DCs, are widely thought cross present antigens on MHC class I (MHCI) molecules more efficiently than other DC populations. If true, it is unclear whether this reflects specialization for presentation or a generally enhanced ability MHCI. We compared by DCs with BDCA1(+) using quantitative approach whereby were targeted distinct intracellular compartments receptor-mediated internalization. As expected, superior at...
The use of tumor-derived proteins as cancer vaccines is complicated by tolerance to these self-antigens. Tolerance may be broken immunization with activated, autologous, ex vivo generated and antigen-loaded, antigen-presenting cells (APC); however, targeting tumor antigen directly APC in would a less strategy. We wished test whether targeted delivery an otherwise poorly immunogenic, soluble through their mannose receptors (MR) induce clinically relevant immunity.Two phase I studies were...
Protein vaccines, if rendered immunogenic, would facilitate vaccine development against HIV and other pathogens. We compared in nonhuman primates (NHPs) immune responses to Gag p24 within 3G9 antibody DEC205 (“DEC-HIV p24”), an uptake receptor on dendritic cells, nontargeted protein, with or without poly ICLC, a synthetic double stranded RNA, as adjuvant. Priming s.c. 60 μg of both vaccines elicited potent CD4 + T cells secreting IL-2, IFN-γ, TNF-α, which also proliferated. The increased...
Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is novel, first-in-class, agonist CD27 antibody stimulates the pathway, which results in T-cell activation antitumor activity tumor models. This first-in-human, dose-escalation expansion study evaluated safety, pharmacology, of varlilumab patients with advanced solid tumors. Methods...
Abstract The ability of cancer cells to ensure T-cell exclusion from the tumor microenvironment is a significant mechanism resistance anti-PD-1/PD-L1 therapy. Evidence indicates crucial roles Batf3-dependent conventional type-1 dendritic (cDC1s) for inducing antitumor immunity; however, strategies maximize cDC1 engagement remain elusive. Here, using multiple orthotopic mouse models resistant anti-PD-L1-therapy, we are testing hypothesis that in situ induction and activation tumor-residing...
Glycoprotein NMB (gpNMB), a novel transmembrane protein overexpressed in 40% to 60% of breast cancers, promotes metastases animal models and is prognostic marker poor outcome patients. The antibody-drug conjugate glembatumumab vedotin consists fully human anti-gpNMB monoclonal antibody, conjugated via cleavable linker monomethyl auristatin E. Glembatumumab generally well tolerated, with observed objective responses advanced melanoma. This is, our knowledge, the first study cancer.Eligible...
PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy, yet frequency responding patients is limited by inadequate T-cell priming secondary to a paucity activatory dendritic cells (DC). DC signals can be bypassed CD27 agonists, and we therefore investigated if effectiveness anti-PD-1/L1 could improved combining with agonist anti-CD27 monoclonal antibodies (mAb).